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ABSTRACT 
Background 
The Global Gynaecological Oncology Surgical Outcomes Collaborative aims to develop a network of 
gynaecological oncology surgeons, surgical departments and other interested parties that will have 
the long-term ability to collaborate on outcome studies. Presented is the protocol for the first 
collaborative study.  
Primary objective 
To evaluate international variation in thirty-day post-operative morbidity and mortality following 
gynaecological oncology surgery between very high/high and medium/low human development 
index country settings. 
Hypothesis 
There is no variation in post-operative morbidity and mortality following gynaecological oncology 
surgery between very high/high and medium/low human development index country settings. 
Study design 
International, multi-centre, prospective cohort study. Patient data will be collected over a 
consecutive thirty-day period through gynaecological oncology multidisciplinary teams/tumour 
boards and clinics across different human development index country groups. All data is collected on 
a customised, secure, password protected, central REDCap database. 
Major inclusion/exclusion criteria 
Inclusion criteria include women aged >18 years undergoing elective/emergency, curative/palliative 
surgery for primary/recurrent tubo-ovarian/peritoneal, endometrial, cervical, vulval, vaginal, 
gestational trophoblastic malignancies. Surgical modality may be open, minimal access 
(laparoscopic/robotic), or vaginal.  
Primary endpoint 
Thirty-day post-operative morbidity and mortality defined as per Clavien-Dindo classification system. 
Sample size 
1100 (550/arm). 
Estimated dates for completing accrual and presenting results 
It is estimated recruitment will be completed by 2022 and results published by 2023. 
Trial registration  
ClinicalTrials.gov registry: NCT04579861 (https://clinicaltrials.gov/ct2/show/NCT04579861). 
PRECIS 
GO SOAR1 is a prospective study evaluating international variations in post-operative morbidity and 
mortality rates following gynaecological oncology surgery. 
 
HIGHLIGHTS 
1. The GO SOAR Collaborative aims to improve surgical outcomes through collaborative 
research. 
2. The GO SOAR international database will help standardise surgical outcome reporting. 





In 2018 globally, the prevalence, incidence and mortality of gynaecological oncology cancers (cervix, 
endometrial, tubo-ovarian, vulval, vaginal) were 25.18 per 100 000 (954 439 cases), 29.35 per 100 
000 (1 309 165 cases) and 13.03 per 100 000 (609 377 cases), respectively. Gynaecological cancers 
collectively after breast cancer account for the second greatest disease burden amongst all female 
cancers and by the year 2040, incidence is set to rise by 69%. Annually, 45% of all individuals 
diagnosed with cancer undergo surgery with curative intent. This amounts to 589 124 cases per 
annum of gynaecological cancer surgery worldwide. Hence due to the current and growing disease 
burden of gynaecological malignancies, surgical care for gynaecological malignancies is an 
indispensable component of a functioning health system.1-4 However surgery has historically had a 
disproportionately low profile in global health priorities at the World Health Organization  due to the 
erroneous perception that it is a high cost intervention benefitting a small segment of society. The 
recent interest in surgical outcomes has been prompted by the recognition that conditions 
amenable to surgery such as gynaecological malignancies are important public health conditions, 
and that there are disparities in access to life saving and disability preventing surgeries particularly 
for rural and marginalised populations in medium/low human development index countries 
representing unmet surgical needs. The World Health Organization and the World Bank, have 
highlighted surgery as an important component for global health development.3 However, surgical 
care requires coordination of skilled human resources, specialised supplies and infrastructure 
including multicentre, international collaborations for the purpose of research to inform 
international policies.4 It is estimated that less than 25% of patients with cancer have access to safe, 
affordable, and timely surgery. Whilst death rates from cancer are decreasing in very high/high 
human development index countries, the opposite is true in medium/low human development index 
countries and up to 1.5% gross domestic product is lost because of cancer in some medium/low 
settings.5, 6 
 
Despite 45% of women with gynaecological malignancies receiving surgical care with curative intent, 
safety and quality of care remain poorly measured and a low priority in many medium/low human 
development index countries. In addition, there is a lack of standardised gynaecological oncology 
surgical data globally and a shortage of patient level data. Gynaecological oncology surgical 
outcomes data, is not located or reported in any standardised way and requires information to be 
compiled from multiple agencies, ministries, health reports and published literature, as there is no 
central source for collecting or reporting. In addition, collected data does not take into account 
country specific epidemiological factors.  
 
Detecting variations associated with outcomes following gynaecological oncology surgeries, and 
modifiable practices associated with these variations, are likely to act as surrogate markers for best 
performance of gynaecological oncology surgical units.7, 8 Globally relevant risk factors for variations 
in outcomes relate to the training of the operating surgeon, availability of investigations, use of 
safety checklists, equipment and access to critical care facilities.9-11 
 
A prospective audit of surgical outcomes following gynaecological oncology surgery in the United 
Kingdom (UKGOSOC: United Kingdom Gynaecological Oncology Surgical Outcomes and 
Complications),12-14 a very high human development index country, may lack relevance and 
comparability in medium/low human development index countries or indeed other very high/high 
human development index countries which do not have a nationalised government funded health 
care system but private healthcare. Whilst the GlobalSurg collaborative has set up a consortium of 
general surgeons investigating surgical outcomes following general surgery, this has not included 
gynaecological oncology. 
 
The Global Gynaecological Oncology Surgical Outcomes Collaborative (GO SOAR) aims to 
supplement the World Health Organization Global Initiative for Emergency and Essential Surgical 
Care by providing risk adjusted patient level outcome data to advise human development index 
country group specific policy formation and develop educational resources to reduce morbidity and 
mortality from gynaecological oncology surgery thereby addressing an urgent unmet need within 
gynaecological oncology. In addition, GO SOAR will develop a network of gynaecological oncology 
surgeons, surgical departments and other interested parties that will have the long-term ability to 
collaborate on future outcome studies, including randomised trials. Widespread provision of 
protocols and supporting educational materials will empower individual practitioners to participate 
and will facilitate audit and research capacity building in regions that currently lack local 
opportunities for development.  
 
We present the protocol for the first GO SOAR collaborative study (GO SOAR1) which evaluates 
international variation of post-operative morbidity and mortality rates following gynaecological 
oncology surgery between country groups defined by human development index. The full protocol 
has also been registered at https://clinicaltrials.gov/ct2/show/NCT04579861 (ClinicalTrials.gov 
registry: NCT04579861).  
 
Our hypothesis is that there is no variation in morbidity and mortality following gynaecological 




Study design is that of an international, multicentre, prospective, observational, cohort study. There 
are one hundred sites planned (nine currently active and an additional fifty-six participating sites 
currently in the set up phase). Funding: The NHS Grampian Endowment Fund; Medtronic; Karl Storz. 
 
Participants 
Inclusion criteria include women aged >18 years undergoing curative, curative attempted but then 
abandoned (open/close laparotomy) or palliative surgery for primary or recurrent tubo-
ovarian/peritoneal, endometrial, cervical, vulval, vaginal, gestational trophoblastic malignancies. 
Surgical modality may be open, minimal access (laparoscopic/robotic), minimal access converted to 
open or vaginal. Both elective and emergency cases are included. Surgeries where pre-operative 
pathology was thought to be benign but malignancy was subsequently confirmed on histopathology 
post-operatively are also eligible. 
 
Objectives  
The primary objectives are to evaluate international variation in post-operative morbidity and 
mortality rates following gynaecological oncology surgery between country groups defined by the 
human development index. This is a composite index of life expectancy, education, and per capita 
income indicators, used to rank countries into four tiers of human development: very high, high, 
medium, low. Secondary objectives include intra-operative morbidity/mortality, histological 
clearance rates following cytoreductive surgery and to identify human development index group 




Primary endpoints are thirty-day post-operative morbidity/mortality defined as per the Clavien-
Dindo classification system.15 Secondary endpoints include intra-operative morbidity/mortality, 
tumour clearance and comparison of current practice against selected tumour specific audit 
standards derived (where available) from the European Society of Gynaecological Oncology 
guidelines for the diagnosis, investigation and management of gynaecological cancers (table 1). 
 
Site selection strategy 
To ensure surgical outcome data collected are representative of care received in each country, 
attempts will be made where possible to recruit large/medium/small centres performing 
gynaecological oncology surgery in a 1:1:1 ratio. Centres will be defined according to surgical 
caseload as follows: large >150, medium 75-149, small <74 new surgical gynaecological cancer cases 
per annum. Large centre threshold of >150 was set as per European Society of Gynaecological 
Oncology training centre accreditation criteria 
 
Patient data will be collected over a consecutive thirty-day period through gynaecological oncology 
multidisciplinary teams/tumour boards and clinics across different human development index 
country groups. This collaborative model for a snapshot clinical audit is well established. It is vital 
that all patients operated on during the consecutive thirty day period are entered onto the 
database. Data will not be presented at the level of individual surgeon/site. Additional data entry 
(beyond thirty-days) is encouraged and may take place at the discretion of the participating site. All 
patients are followed up as per local protocols for thirty-days post-operatively to identify post-
surgical morbidity/mortality. In the absence of established local follow-up protocols, at the very 
minimum, a telephone call to the patient within the thirty-day follow up period from surgery is 
required to capture morbidity data.  
 
Data quality and validation 
To ensure high data quality, a detailed protocol has been produced and published online 
(https://clinicaltrials.gov/ct2/show/NCT04579861). Collaborators are encouraged to perform data 
input in real time using the REDCap system. Data quality rules built into the REDCap database, will 
also ensure data quality and highlight disparities in data fields to the local collaborator for review. 
Training is available to collaborators prior to the commencement of data collection and entry. 
 
Data validation is completed in three stages across a representative sample of centres. First, centres 
self report key processes used to identify and follow-up patients. Second, independent validators 
locally not part of the recruiting teams quantitatively report case ascertainment and sampled data 
accuracy. Third, local teams are interviewed by the central coordinating team to qualitatively assess 
collaborator engagement and data collection processes. 
 
Sample size 
Whilst there is a paucity of data on morbidity and mortality following gynaecological oncology 
surgery in medium/low human development index country settings, data for very high/high human 
development index country settings suggest morbidity is 26% and mortality 2%. Using this as a 
baseline, a sample size of 1100 (550/arm) inflated by 20% to account for missing data and loss to 
follow-up, at 90% power, α=0.05, will be able to determine a 10% point difference in thirty-day post-
operative morbidity and mortality following gynaecological oncology surgery between very 




Baseline characteristics will be calculated using descriptive statistics. Appropriate statistical tests will 
be used for analyses. Chi-square tests will compare categorical variables and t-Test (parametric) and 
Mann Whitney (non-parametric) tests will compare continuous outcome variables between groups. 
Random effects models adjusted for covariates/confounders will be used to compare outcomes 
between human development index groups over time. Progress on data collection and summary 
statistics will be reported to the international steering committee at their regular meetings. Analysis 
of the full data set will be undertaken at the end of the study.  
 
DISCUSSION 
The GO SOAR Collaborative plans to implement a series of internationally collaborative studies. This 
protocol describes the first GO SOAR collaborative study which is a multicentre, prospective cohort 
study evaluating international variation in post-operative morbidity and mortality following 
gynaecological oncology surgery between human development index country groups.  
 
The World Health Organization’s analysis of excess surgical mortality established three significant 
findings. First, surgical interventions take place on a massive and previously unrecognised scale in all 
countries and resource settings. Second, the inequity in service provision amongst countries and 
settings is dramatic. Third, little is known about the indications for, quality, safety, and outcomes of 
surgical care. Whilst the GlobalSurg Collaborative has made headway investigating these issues 
within the context of general surgery, for gynaecological oncology there is a paucity of comparable 
international data across different human development index country groups on surgical outcomes. 
The first GO SOAR study aims to generate data to help fill this knowledge gap. Despite the likely 
increased risk of morbidity and mortality for patients undergoing gynaecological oncology surgery in 
medium/low human development income country settings, robust, empirical data are currently 
unavailable. Additionally, in countries with limited resources, applicability of gynaecological 
oncology surgical guidelines are yet to be tested. By using a collaborative model and a thirty-day 
snapshot data collection period, our study will recruit sufficient patients to measure this, whilst 
avoiding over burdening low resource centres that may otherwise be unable to participate. 
Investigating the morbidity and mortality caused by gynaecological oncology surgery globally, this 
study will provide a platform to build future quality improvement programmes and interventional 
trials. A detailed study protocol, training, data quality control and validation will ensure 
standardisation to deliver a reliable and accurate data set. This study will be delivered using an 
international multidisciplinary collaborative network of healthcare researchers and clinicians. 
 
The four key mandates of the GO SOAR Collaborative are to 1) set the research agenda through 
research prioritisation in gynaecological oncology, 2) gather high quality data via a centralised 
database accessible to all sites that perform gynaecological oncology surgery, 3) build sustainable 
international research by producing protocols/guidelines, and 4) train the researchers and leaders of 
tomorrow by providing open access to all GO SOAR training materials. In combination, this in turn 
will help provide safe and effective surgical care in gynaecological oncology globally. 
 
The GO SOAR international database will help standardise surgical outcome reporting. Standardised 
reporting renders comparable data across different healthcare systems for more extensive research 
and analysis. The international database will also allow all participating centres/units performing 
gynaecological oncology surgery to audit their local practice and implement local changes whilst at 
the same time contribute patient level data reported using standardised electronic forms for use in 
global GO SOAR studies which will help inform and drive policy change internationally. 
 
Often research in gynaecological oncology takes place within very high/high human development 
index country settings with outcomes difficult to reproduce and recommendations difficult to 
implement in medium/low human development index countries with limited resources. Inclusion of 
medium/low human development index country partners are vital to be able to identify context 
specific solutions and to ensure high quality surgical care in a low resource setting. 
 
In conclusion, the GO SOAR Collaborative aims to improve surgical outcomes through collaborative 
research. It will provide risk adjusted patient level outcome data collected via a centralised database 
to advise human development index country group specific policy formation. 
 
Contribution to authorship 
Collaborative conception and design: FG. 
Study conception and design: FG. 
Protocol development: FG, DC, NB, PR, PK, AS, SP, OB. 
Database development: FG, NB, PK, AS, SP, OB, DC. 
Steering committee: FG, DC, PR, NB, PK, AS, SP, OB. 
Study management: FG, NB, PK, AS, SP, OB.  
Preparation of tables and figures: FG. 
Initial draft of manuscript: FG. 
Statistical aspects: FG, OB. 
Manuscript writing and approval: All authors. 
 
Disclaimers/Conflict of interest statement 
FG declares funding from The NHS Grampian Endowment Fund, Medtronic, Karl Storz for the GO 
SOAR1 study and is Chief Investigator. All other authors declare no conflict of interest. 
 
Funding 
The NHS Grampian Endowment Fund; Medtronic; Karl Storz. 
 
Ethical approval 
The study has been approved and registered with the Quality Improvement & Assurance Team 
(QIAT) at NHS Grampian (project ID 5009), UK.  
 
Acknowledgements 
We are grateful to the members of the international steering committee. We acknowledge support 
provided by a number stakeholders including the European Network of Young Gynae Oncologists 
(ENYGO), Society of Gynecologic Oncology (SGO) and Target Ovarian Cancer. We are grateful to the 
study sponsor NHS Grampian and our funders The NHS Grampian Endowment Fund, Medtronic and 
Karl Storz. We are also grateful to Dr Mohamedraed Elshami who is the lead study coordinator for 
the Middle East and North Africa region as well as our country lead study coordinators: Dr Mahmoud 
Saad and Dr Ahmed Nafea (joint leads for Egypt), Dr Muhammed Elhadi (Libya), Dr Alaa Ismail 
(Palestine), Dr Hamza Al-Naggar (Yemen). In addition, we are grateful to all our collaborators: Dr 
Darin Maria Cecilia (British Hospital of Buenos Aires, Argentina), Dr Maximilian Lanner (Kardinal 
Schwarzenberg Klinikum, Austria), Dr Andrei Pletnev (N.N. Alexandrov National Cancer Centre of 
Belarus, Belarus), Dr Basel Refky (Mansoura University, Egypt), Dr Abdelazez Elkady (Menofia 
University Faculty of Medicine, Egypt), Dr Tarek Karkour (El Shatby Hospital For Obstetrics & 
Gynecology, Egypt), Dr Hazim Salah Ali (Ahmed Ashram Abdel-Karem Hospital, Egypt), Dr Sherief 
Ghozy (El-Sheikh Zayed Specialized Hospital, Egypt), Dr Sameh Daghash (Armed Forces Hospital in 
Alexandria, Egypt), Dr Mohamed Hamed Elmelegy (Hospital of Faculty of Medicine Menofia 
University, Egypt), Dr Eman Monier (El Shatby Maternity Hospital, Egypt), Dr Mohammad Abdel-
Rahman Mohammad (South Valley university Hospitals, Egypt), Dr Domenico Ferraioli (Cancer 
Center Leon Berard, France), Tanja Nikolova (Academic Teaching Hospital of Heidelberg University, 
Germany), Dr Stamatios Petousis (Aristotle University of Thessaloniki, Hippokration General Hospital, 
Greece), Charalampos Theofanakis (General Hospital of Athens Alexandra, Greece), Dr Jagannth 
Mishra (Acharya Harihar Postgraduate Institute of Cancer, India), Dr Vadaparty Annapurna (Sri 
Shankara Cancer Hospital and Research Centre, India), Dr Mariam Anjum Ifthikar (Yenepoya 
Hospital, India), Dr Anik Ghosh (Tata Medical Center, India), Dr Ajay Chanakya Vallabhaneni (Krishna 
Institute of Medical Sciences, India), Dr Bijoy Kar (Gujarat Cancer Research Institute, India), Dr Alyaa 
Al-khafaji (Babel Maternity and Children Teaching Hospital, Iraq), Dr Ali Al-Isawi (Babel Maternity 
and Children Teaching Hospital, Iraq), Dr Michael O'Leary (Galway University Hospital, Ireland), Dr 
Fabio Martinelli (IRCCS Foundation National Cancer Institute, Italy), Dr Martina Arcieri (A.O.U. 
Policlinico G. Martino, Italy), Dr Stefano Restaino (University Hospital Santa Maria della Misericordia, 
Italy), Dr Anna Fagotti (Policlinico Agostino Gemelli IRCCS, Italy), Dr Edoardo Cola (Ospedale di 
Macerata, Italy), Dr Stefano Bogliolo (SC Ostetricia e Ginecologia - Ospedale di Lavagna , Italy), Dr 
Qais Shatnawi (King Hussein Cancer Center, Jordan), Dr Suha Alka'Abneh (Al Karak Public Hospital, 
Jordan), Dr Amer Mahmoud Sindiani (King Abdullah University Hospital, Jordan), Dr Wafa Alsardieh 
(King Abdullah University Hospital, Jordan), Dr Abdulrahman Qasem (Al-Basheer Hospital, Jordan), Dr 
Shatha Husain (Islamic Hospital, Jordan), Dr Maherah Kamarudin (University of Malaya Medical 
Centre, Malaysia), Dr Moniba Korch (University Hospital Mohammed VI of Marrakech, Morocco), Dr 
Ishak Lawal (Federal Medical Centre Birnin-Kebbi, Nigeria), Dr Adeyemi Okunowo (Lagos University 
Teaching Hospital, Nigeria), Dr Mohammed Alkronz (Baraa Hajjaj, Palestine), Dr Madjed Khalil Abu 
Amer (Nasser Medical Complex, Palestine), Dr Mashhour Nassan (Al-Makassed Hospital, Palestine), 
Dr Khalil Abuzaina (Governmental Hebron Hospital, Palestine), Dr Farah Bilal Shaheen 
(Governmental Hebron Hospital, Palestine), Dr Subhi Maher Abusharkh (Muhammad Ali Al-
Muhtaseb Governmental Hospital, Palestine), Dr Waleed Abu Hatab (Palestinian Red Crescent 
Society, Palestine), Dr Najib Salameh (Beit Jala Governmental Hospital, Palestine), Dr Adnan Radi (Al-
Awda Hospital UHWC), Dr João Casanova (Champalimaud Foundation, Portugal), Kamil Zalewski 
(Świętokrzyskie Cancer Centre, Poland), Dr Amel Yousif (Hamad Medical Corporation, Qatar), Dr Igor 
Govorov (Almazov National Medical Research Centre, Russia), Dr Ahmed Abu-Zaid (King Faisal 
Specialist Hospital and Research Centre, Saudi Arabia), Dr Susan Alghamdi (King Fahad Specialist 
Hospital, Saudi Arabia), Dr Antonio Gil Moreno (Vall d'Hebron University Hospital, Spain), Dr Natalia 
Rodriguez (Vall d'Hebron University Hospital, Spain), Dr Felix Boria (Clinica Universidad de Navarra, 
Spain), Dr Zoia Razumova (Karolinska Institute at Karolinska University Hospital, Sweden), Dr Zuheir 
Alshehabi (Tishreen University Hospital, Syria), Dr Bassam Hassan (Tishreen University Hospital, 
Syria), Dr Hamdi Nawfal (Aleppo University Hospital of Obstetrics and Gynecology, Syria), Dr Amr 
Hamza (Aleppo University Hospital of Obstetrics and Gynecology, Syria), Dr Seda Şahin Aker (Kayseri 
City Training and Education Hospital, Turkey), Dr Salih Taskin (Ankara University Hospital, Turkey), 
Ilker Kahramanoglu (Emsey Hospital, Turkey), Ilker Selcuk (Ankara City Hospital, Turkey), Dr 
Mahalakshmi Gurumurthy (NHS Grampian, United Kingdom), Dr Mary Cairns (NHS Grampian, United 
Kingdom), Dr Lori McPherson (NHS Grampian, United Kingdom), Professor Sadaf Ghaem-Maghami 
(Imperial College Healthcare NHS Trust, United Kingdom), Dr John Butler (The Royal Marsden 
Hospital, United Kingdom), Dr Christine Ang (Gateshead Health NHS Foundation Trust, United 
Kingdom), Dr Aarti Sharma (University Hospital of Wales Cardiff, United Kingdom), Dr Hamza Al-
Naggar (Al-Thawra Modern General Hospital, Yemen), Dr Sara Saif (Alsabeen Maternal Hospital, 
Yemen), Dr Marwan Al-Sarawy (Althawrah hospital, Yemen), Dr Ibrahim Al-Raimi (University of 




1. Farmer PE, Kim JY. Surgery and global health: a view from beyond the OR. World journal of 
surgery. 2008 Apr;32(4):533-6. 
2. Luboga S, Macfarlane SB, von Schreeb J, Kruk ME, Cherian MN, Bergström S, et al. Increasing 
access to surgical services in sub-saharan Africa: priorities for national and international agencies 
recommended by the Bellagio Essential Surgery Group. PLoS medicine. 2009 Dec;6(12):e1000200. 
3. Meara JG, Leather AJ, Hagander L, Alkire BC, Alonso N, Ameh EA, et al. Global Surgery 2030: 
evidence and solutions for achieving health, welfare, and economic development. Lancet (London, 
England). 2015 Aug 8;386(9993):569-624. 
4. Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, et al. Size and 
distribution of the global volume of surgery in 2012. Bulletin of the World Health Organization. 2016 
Mar 1;94(3):201-9f. 
5. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, 
and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and 
Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the 
Global Burden of Disease Study. JAMA oncology. 2017 Apr 1;3(4):524-48. 
6. Alkire BC, Raykar NP, Shrime MG, Weiser TG, Bickler SW, Rose JA, et al. Global access to 
surgical care: a modelling study. The Lancet Global health. 2015 Jun;3(6):e316-23. 
7. Symons NR, Moorthy K, Almoudaris AM, Bottle A, Aylin P, Vincent CA, et al. Mortality in 
high-risk emergency general surgical admissions. The British journal of surgery. 2013 
Sep;100(10):1318-25. 
8. Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C, et al. Mortality after surgery in 
Europe: a 7 day cohort study. Lancet (London, England). 2012 Sep 22;380(9847):1059-65. 
9. Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat AH, Dellinger EP, et al. A surgical safety 
checklist to reduce morbidity and mortality in a global population. The New England journal of 
medicine. 2009 Jan 29;360(5):491-9. 
10. Funk LM, Weiser TG, Berry WR, Lipsitz SR, Merry AF, Enright AC, et al. Global operating 
theatre distribution and pulse oximetry supply: an estimation from reported data. Lancet (London, 
England). 2010 Sep 25;376(9746):1055-61. 
11. Kwok AC, Funk LM, Baltaga R, Lipsitz SR, Merry AF, Dziekan G, et al. Implementation of the 
World Health Organization surgical safety checklist, including introduction of pulse oximetry, in a 
resource-limited setting. Annals of surgery. 2013 Apr;257(4):633-9. 
12. Burnell M, Iyer R, Gentry-Maharaj A, Nordin A, Liston R, Manchanda R, et al. Benchmarking 
of surgical complications in gynaecological oncology: prospective multicentre study. BJOG : an 
international journal of obstetrics and gynaecology. 2016 Dec;123(13):2171-80. 
13. Iyer R, Gentry-Maharaj A, Nordin A, Burnell M, Liston R, Manchanda R, et al. Predictors of 
complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOC-UK 
gynaecological oncology surgical outcomes and complications). British journal of cancer. 2015 Feb 
3;112(3):475-84. 
14. Iyer R, Gentry-Maharaj A, Nordin A, Liston R, Burnell M, Das N, et al. Patient-reporting 
improves estimates of postoperative complication rates: a prospective cohort study in 
gynaecological oncology. British journal of cancer. 2013 Aug 6;109(3):623-32. 
15. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal 




Figure 1: Study flowchart 
GO SOAR - Global Gynaecological Oncology Surgical Outcomes Collaborative; FIGO – International 
Federation of Gynecology and Obstetrics. 
  
Table 1: Tumour specific measurable audit standards 
Ovarian 
Surgery performed by a gynaecologic oncologist or a trained surgeon specifically dedicated to 
gynaecological cancer management.  
Treatment planned and reviewed at a Multidisciplinary Team Meeting.  
Endometrial 
Complete macroscopic cytoreduction and comprehensive staging is recommended in advanced 
endometrial cancer.  
Multimodality management should be considered for the treatment of advanced endometrial cancer 
when surgery may significantly impair vaginal function. 
Cervical 
Surgery performed or supervised by a certified gynaecologic oncologist or a trained surgeon 
dedicated to gynaecological cancer.  
Treatment discussed at a multi-disciplinary team meeting. 
Vulval 
Surgery performed or supervised by a certified gynaecologic oncologist or a trained surgeon 
dedicated to gynaecological cancer.  
Treatment discussed at a multi-disciplinary team meeting.  
Vaginal – in the absence of international guidelines on surgical management, the following is 
proposed. 
Surgery performed or supervised by a certified gynaecologic oncologist or a trained surgeon 
dedicated to gynaecological cancer.  
Treatment discussed at a multi-disciplinary team meeting.  
Gestational trophoblastic malignancies - in the absence of international guidelines on surgical 
management, the following is proposed. 
Surgery performed or supervised by a certified gynaecologic oncologist or a trained surgeon 
dedicated to gynaecological cancer.  
Treatment discussed at a multi-disciplinary team meeting.  
 
